Mostrar el registro sencillo del ítem
| dc.contributor.author | Martin-Moro, Fernando | |
| dc.contributor.author | Muntanola, Ana | |
| dc.contributor.author | Gutiérrez, Xabier | |
| dc.contributor.author | Vázquez, María-Sofia | |
| dc.contributor.author | Morais, Lucía | |
| dc.contributor.author | Amarika, Itxaso | |
| dc.contributor.author | Diez-Feijoo, Ramon | |
| dc.contributor.author | Bastos-Oreiro, Mariana | |
| dc.contributor.author | de-la-Cruz, Beatriz | |
| dc.contributor.author | Marco-Ayala, Javier | |
| dc.contributor.author | Ramos, Sergio | |
| dc.contributor.author | Jiménez-Ubieto, Ana | |
| dc.contributor.author | Galindo-Navarro, Pablo | |
| dc.contributor.author | Correa, Juan-Gonzalo | |
| dc.contributor.author | Lavilla, Esperanza | |
| dc.contributor.author | García-Herce, Cristina | |
| dc.contributor.author | Moreno, Miriam | |
| dc.contributor.author | Domingo-Domenech, Eva | |
| dc.contributor.author | Domínguez, Nazaret | |
| dc.contributor.author | Alonso, Aranzazu | |
| dc.contributor.author | Otero, María-José | |
| dc.contributor.author | Comai, Alessandra | |
| dc.contributor.author | Bengochea, María-Luisa | |
| dc.contributor.author | Da-Ros, Carolina-Villegas | |
| dc.contributor.author | Gutiérrez, Norma-C | |
| dc.contributor.author | Lluch, Rafael | |
| dc.contributor.author | Fernández-Luis, Sara | |
| dc.contributor.author | Soler, Joan-Alfons | |
| dc.contributor.author | Cannata-Ortiz, M-Jimena | |
| dc.contributor.author | Medina, Ángeles | |
| dc.contributor.author | Martin-Consuegra, Sofia | |
| dc.contributor.author | Aceituno, Marta | |
| dc.contributor.author | Villafuerte, Paola | |
| dc.contributor.author | de-Miguel, Dunia | |
| dc.contributor.author | Arguinano, José-María | |
| dc.contributor.author | López, Javier | |
| dc.contributor.author | Villalon, Lucía | |
| dc.contributor.author | Gulino, Horacio | |
| dc.contributor.author | López-Guillermo, Armando | |
| dc.contributor.author | Salar, Antonio | |
| dc.date.accessioned | 2026-11-11T09:07:21Z | |
| dc.date.available | 2026-11-11T09:07:21Z | |
| dc.date.issued | 2026-10-27 | |
| dc.identifier.citation | Martin-Moro F, Muntañola A, Gutiérrez X, Vázquez MS, Morais L, Amarika I, et al. Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. Blood Advances. 27 de octubre de 2026;10(20):7036-47. doi:10.1182/bloodadvances.2026020480 | |
| dc.identifier.issn | 2473-9529 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29207 | |
| dc.description.abstract | There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least 1 previous anti-CD20-based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), mucosa-associated lymphoid tissue (18.9%), nodal (19.8%), and nonclassifiable (6%). The median number of previous lines of therapy (LoT) was 1.5 (range, 1-7); 26% of patients had MZL refractory to the immediately preceding line, and 59% experienced progression of disease within 24 months (POD24) to frontline therapy. In total, 31 patients (26.3%) would not have met MAGNOLIA trial eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA trial eligibility. Fewer previous LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than those with progressing disease (P< .01). Adverse events (AEs) were reported in 34.1% of patients (grade ?3 in 14.4%). MAGNOLIA trial-ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (P = .04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Lymphoma, B-Cell, Marginal Zone/drug therapy/mortality/pathology | |
| dc.subject.mesh | Spain | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Aged, 80 and over | |
| dc.subject.mesh | Treatment Outcome | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Retrospective Studies | |
| dc.subject.mesh | Recurrence | |
| dc.subject.mesh | Neoplasm Recurrence, Local/drug therapy | |
| dc.title | Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42641154 | |
| dc.relation.publisherversion | https://ashpublications.org/bloodadvances/article/10/20/7036/570523/Real-world-effectiveness-and-safety-of | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1182/bloodadvances.2026020480 | |
| dc.journal.title | Blood Advances | |
| dc.identifier.essn | 2473-9537 |